# Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

> **NCT00460460** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 75 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** AZD4877

## Key facts

- **NCT ID:** NCT00460460
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 75 (ESTIMATED)
- **Why stopped:** Study was terminated due to low enrollment
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460460, "Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00460460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*